UPDATE: BMO Capital Starts Pfizer (PFE) at Outperform

BMO Capital analyst Evan David Seigerman initiates coverage on Pfizer (NYSE: PFE) with a Outperform rating and a price target of $60.00.

The analyst comments "We initiate coverage of Pfizer with an Outperform Rating and $60/share target price, based on: 1) our positive view of the company’s top-line growth and potential for margin leverage through the mid-2020s; 2) a longer-than-projected tail from the COVID-19 vaccine business (and subsequent products from the platform thereafter); 3) rich pipeline, with multiple de-risking catalysts near term; and 4) financially solid fundamentals with an attractive valuation, relative to peers."

For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.

Shares of Pfizer closed at $50.87 yesterday.

You May Also Be Interested In

• Canaccord Starts Infleqtion, Inc (INFQ) at Buy
• Domino's Pizza (DPZ) PT Lowered to $375 at UBS on 'Near-Term Category/Brand Headwinds'
• Exelixis (EXEL) PT Raised to $52 at UBS on Upcoming Catalysts